Inflammatory bowel disease (IBD) describes a group of disorders that cause the intestines to become inflamed. There are two main types of IBD: ulcerative colitis and Crohn’s disease. These two types of IBD are increasingly prevalent, relapsing and remitting inflammatory bowel diseases with variable disease causes and complications.
The exact cause of IBD is unknown. However, IBD is the result of a dysregulation of the immune system. In people with IBD, their immune system responds incorrectly to environmental triggers that pose no threat to the body. This reaction causes inflammation of the gastrointestinal tract and causes symptoms that include:
- Persistent diarrhea
- Abdominal pain
- Rectal bleeding
- Weight loss
Precision Medicine for IBD
Current management strategies for IBD focus on remission and the prevention of flares. However, many people fail to respond, have frequent relapses, and develop significant complications when following the standard label on anti-TNF monoclonal antibody therapy, such as infliximab.
Anti-TNF monoclonal antibody therapy is an effective treatment in selected patients. While initial response rates for infliximab are relatively good, some patients will not respond, and some will lose response over time.
Precision medicine refers to the “tailoring of medical treatment to the individual characteristics of each patient.” Precision medicine encompasses a multidisciplinary data-driven approach that allows physicians to predict more accurately which treatment and prevention strategies will work for that specific individual.
The one-size-fits-all approach for disease treatment and prevention strategies is developed for the average person. However, many factors play a key role in IBD that cause patients to fail off the standard infliximab label if their differences are not considered in treatment.
With precision medicine, physicians can accurately diagnose a disease, enabling an individualized treatment strategy. Targeted treatments also improve patient outcomes by optimizing medication use while preventing drug failure in patients, reducing adverse drug reactions, and lowering overall healthcare costs.
At Baysient, we value the fact that all patients are unique and deserve individual treatments tailored specifically for them, changing as they heal. There is no single dose that is right for all patients. That is why our goal is to provide individualized treatments for patients with improved outcomes at lower costs.
iDose, our cloud-based software, uses Bayesian models, routine lab results, and demographic information to allow physicians to individualize dosing to a specific target trough level. Interested in how iDose can improve your patient outcomes? Schedule a Demo today!